Loading
BI-1607 is an experimental monoclonal antibody from BioInvent International, in phase 2 trials for melanoma, uveal melanoma and HER2-positive breast cancer and other cancers.
BI-1607 is a monoclonal antibody (engineered) from BioInvent International. An engineered anti-FcγRIIB (FCGR2B) antibody intended to enhance efficacy and overcome resistance to existing cancer treatments such as targeted antibodies and checkpoint inhibitors; tested with ipilimumab and pembrolizumab in melanoma and earlier with trastuzumab. Its furthest stage is phase 2, for melanoma, uveal melanoma, HER2-positive breast cancer and HER2-positive gastric cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1b/2a NCT06784648 (melanoma, with ipilimumab and pembrolizumab) active, not recruiting; the earlier trastuzumab combination trial NCT05555251 is terminated (registry, checked 3 Nov 2026). The BI-1607 page is no longer linked from BioInvent's programme menu. Whether it works in people has not been established unless a trial below reports it.
An engineered anti-FcγRIIB (FCGR2B) antibody intended to enhance efficacy and overcome resistance to existing cancer treatments such as targeted antibodies and checkpoint inhibitors; tested with ipilimumab and pembrolizumab in melanoma and earlier with trastuzumab. Connects to FCGR2B.
1.BI-1607 binds FCGR2B.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"BI-1607" OR ABSTRACT:"BI-1607") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BI-1607, not a curated reading list.
Shares FCGR2B, BioInvent International and the tag pipeline.
Shares BioInvent International, Melanoma and the tag pipeline.
Shares Uveal melanoma, Melanoma and the tag pipeline.
Shares BioInvent International, Melanoma and the tag pipeline.
Shares HER2-positive gastric cancer, HER2-positive breast cancer and the tag pipeline.
Shares BioInvent International, Melanoma and the tag pipeline.
Shares HER2-positive gastric cancer, HER2-positive breast cancer and the tag pipeline.
Shares BioInvent International and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/